Search: onr:"swepub:oai:DiVA.org:liu-152524" >
Review on comparati...
Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients
-
- Pathak, Surajit (author)
- Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, India
-
- S, Sushmitha (author)
- Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, India
-
- Banerjee, Antara (author)
- Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, India
-
show more...
-
- Marotta, Francesco (author)
- ReGenera Research Group for Aging-Intervention, Milano, Italy and San Babila Clinic, Healthy Aging Unit by Genomics and Biotechnology, Milano, Italy
-
- Gopinath, Madhumala (author)
- Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, India
-
- Murugesan, Ramachandran (author)
- Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, India
-
- Zhang, Hong (author)
- School of Medicine, Orebro University, Örebro, Sweden
-
- B, Bhavani (author)
- Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, India
-
- Girigoswami, Agnishwar (author)
- Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai, India
-
- Sollano, Jose (author)
- Gastroenterology Department, University of Santo Tomas, Manila, The Philippines
-
- Sun, Xiao-Feng, 1959- (author)
- Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US
-
show less...
-
(creator_code:org_t)
- 2017-11-16
- 2018
- English.
-
In: Oncotarget. - : Impact Journals, LLC. - 1949-2553. ; 9:7, s. 7739-7748
- Related links:
-
https://liu.diva-por... (primary) (Raw object)
-
show more...
-
http://www.oncotarge...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Colorectal cancer, fourth leading form of cancer worldwide and is increasing in alarming rate in the developing countries. Treating colorectal cancer has become a big challenge worldwide and several antibody therapies such as bevacizumab, panitumumab and cetuximab are being used with limited success. Moreover, mutation in KRAS gene which is linked with the colorectal cancer initiation and progression further interferes with the antibody therapies. Considering median progression free survival and overall survival in account, this review focuses to identify the most efficient antibody therapy in combination with chemotherapy (FOLFOX-4) in KRAS mutated colorectal cancer patients. The bevacizumab plus FOLFOX-4 therapy shows about 9.3 months and 8.7 months of progression free survival for KRAS wild and mutant type, respectively. The overall survival is about 34.8 months for wild type whereas for the mutant it is inconclusive for the same therapy. In comparison, panitumumab results in better progression-free survival which is about (9.6 months) and overall survival is about (23.9 months) for the wild type KRAS and the overall survival is about 15.5 months for the mutant KRAS. Cetuximab plus FOLFOX-4 therapy shows about 7.7 months and 5.5 months of progression-free survival for wild type KRAS and mutant type, respectively. Thus, panitumumab shows significant improvement in overall survival rate for wild type KRAS, validating as a cost effective therapeutic for colorectal cancer therapy. This review depicts that panitumumab along with FOLFOX-4 has a higher response in colorectal cancer patients than the either of the two monoclonal antibodies plus FOLFOX-4.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Keyword
- KRAS; bevacizumab; cetuximab; colorectal cancer; panitumumab
Publication and Content Type
- ref (subject category)
- for (subject category)
Find in a library
-
Oncotarget
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Pathak, Surajit
-
S, Sushmitha
-
Banerjee, Antara
-
Marotta, Frances ...
-
Gopinath, Madhum ...
-
Murugesan, Ramac ...
-
show more...
-
Zhang, Hong
-
B, Bhavani
-
Girigoswami, Agn ...
-
Sollano, Jose
-
Sun, Xiao-Feng, ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
- Articles in the publication
-
Oncotarget
- By the university
-
Linköping University